Clinical, immunophenotypic (EGIL31 and TCR subsets32), and genotypic characteristics of adult T-ALL as a function of NOTCH1/FBXW7 status
| . | Total . | NOTCH1 . | FBXW7 . | NOTCH1 and/or FBXW7 . | P . | |||
|---|---|---|---|---|---|---|---|---|
| Mut n (%) . | WT n (%) . | Mut (%) . | WT n (%) . | Mut n (%) . | WT n (%) . | |||
| Total, no. (%) | 232 | 142 (61) | 90 (39) | 46 (20) | 186 (80) | 159 (69) | 73 (31) | |
| TCR subsets analyzed, no. (%) | 189 | |||||||
| Immature | 72 (38) | 42 (58) | 30 (42) | 12 (17) | 60 (83) | 46 (64) | 26 (36) | NS |
| Pre-αβ | 72 (38) | 50 (69) | 22 (31) | 16 (22) | 56 (78) | 57 (79) | 15 (21) | .008* |
| TCR+ | 45 (24) | 20 (44) | 25 (56) | 9 (20) | 36 (80) | 25 (56) | 20 (44) | NS |
| EGIL, no. (%) | 224 | |||||||
| 1 or 2 | 73 (32) | 43 (59) | 30 (41) | 8 (11) | 65 (89) | 46 (63) | 27 (37) | NS |
| 3 | 125 (56) | 86 (69) | 39 (31) | 33 (26) | 92 (74) | 96 (77) | 29 (23) | .008* |
| 4 | 26 (12) | 10 (38) | 16 (62) | 4 (15) | 22 (85) | 14 (54) | 12 (46) | NS |
| Genotype subsets analyzed, no. (%) | 214 | |||||||
| CALM-AF10 | 13 (6) | 4 (31) | 9 (69) | 4 (31) | 9 (69) | 6 (46) | 7 (54) | NS |
| SIL-TAL1 | 16 (7) | 7 (44) | 9 (56) | 2 (12) | 14 (88) | 8 (50) | 8 (50) | NS |
| TLX1 | 44 (21) | 34 (77) | 10 (23) | 7 (16) | 37 (84) | 37 (84) | 7 (16) | .007* |
| TLX3 | 23 (11) | 15 (65) | 8 (35) | 8 (35) | 15 (65) | 19 (83) | 4 (17) | NS |
| None of the above | 118 (55) | 68 (58) | 50 (42) | 22 (19) | 96 (81) | 74 (63) | 44 (37) | NS |
| Clinical subsets analyzed | ||||||||
| Sex, male, no. (%) | 183 (79) | 114 (80) | 69 (77) | 35 (76) | 148 (80) | 127 (80) | 56 (77) | NS |
| Median age, y | 30 | 29 | 30 | 28 | 30 | 29 | 30 | NS |
| Age > 35 y, no. (%) | 84 (36) | 52 (37) | 32 (36) | 13 (28) | 71 (38) | 56 (35) | 28 (38) | NS |
| WBC, 109/L, median | 48 | 44 | 52 | 37 | 52 | 42 | 76 | NS |
| WBC > 100 × 109/L, no. (%) | 74 (32) | 40 (28) | 34 (38) | 11 (24) | 63 (34) | 43 (27) | 31 (43) | .02* |
| Mediastinal involvement, no. (%) | 105 (48) | 70 (51) | 35 (42) | 26 (56) | 79 (45) | 78 (51) | 27 (40) | NS |
| CNS involvement, no. (%) | 20 (9) | 10 (7) | 10 (11) | 4 (9) | 16 (9) | 13 (8) | 7 (10) | NS |
| CR, no. (%) | 214 (92) | 136 (96) | 78 (87) | 41 (89) | 173 (93) | 150 (94) | 64 (88) | NS |
| Relapse, no. (%) | 94 (44) | 48 (35) | 46 (59) | 18 (44) | 76 (44) | 55 (37) | 39 (61) | .001* |
| . | Total . | NOTCH1 . | FBXW7 . | NOTCH1 and/or FBXW7 . | P . | |||
|---|---|---|---|---|---|---|---|---|
| Mut n (%) . | WT n (%) . | Mut (%) . | WT n (%) . | Mut n (%) . | WT n (%) . | |||
| Total, no. (%) | 232 | 142 (61) | 90 (39) | 46 (20) | 186 (80) | 159 (69) | 73 (31) | |
| TCR subsets analyzed, no. (%) | 189 | |||||||
| Immature | 72 (38) | 42 (58) | 30 (42) | 12 (17) | 60 (83) | 46 (64) | 26 (36) | NS |
| Pre-αβ | 72 (38) | 50 (69) | 22 (31) | 16 (22) | 56 (78) | 57 (79) | 15 (21) | .008* |
| TCR+ | 45 (24) | 20 (44) | 25 (56) | 9 (20) | 36 (80) | 25 (56) | 20 (44) | NS |
| EGIL, no. (%) | 224 | |||||||
| 1 or 2 | 73 (32) | 43 (59) | 30 (41) | 8 (11) | 65 (89) | 46 (63) | 27 (37) | NS |
| 3 | 125 (56) | 86 (69) | 39 (31) | 33 (26) | 92 (74) | 96 (77) | 29 (23) | .008* |
| 4 | 26 (12) | 10 (38) | 16 (62) | 4 (15) | 22 (85) | 14 (54) | 12 (46) | NS |
| Genotype subsets analyzed, no. (%) | 214 | |||||||
| CALM-AF10 | 13 (6) | 4 (31) | 9 (69) | 4 (31) | 9 (69) | 6 (46) | 7 (54) | NS |
| SIL-TAL1 | 16 (7) | 7 (44) | 9 (56) | 2 (12) | 14 (88) | 8 (50) | 8 (50) | NS |
| TLX1 | 44 (21) | 34 (77) | 10 (23) | 7 (16) | 37 (84) | 37 (84) | 7 (16) | .007* |
| TLX3 | 23 (11) | 15 (65) | 8 (35) | 8 (35) | 15 (65) | 19 (83) | 4 (17) | NS |
| None of the above | 118 (55) | 68 (58) | 50 (42) | 22 (19) | 96 (81) | 74 (63) | 44 (37) | NS |
| Clinical subsets analyzed | ||||||||
| Sex, male, no. (%) | 183 (79) | 114 (80) | 69 (77) | 35 (76) | 148 (80) | 127 (80) | 56 (77) | NS |
| Median age, y | 30 | 29 | 30 | 28 | 30 | 29 | 30 | NS |
| Age > 35 y, no. (%) | 84 (36) | 52 (37) | 32 (36) | 13 (28) | 71 (38) | 56 (35) | 28 (38) | NS |
| WBC, 109/L, median | 48 | 44 | 52 | 37 | 52 | 42 | 76 | NS |
| WBC > 100 × 109/L, no. (%) | 74 (32) | 40 (28) | 34 (38) | 11 (24) | 63 (34) | 43 (27) | 31 (43) | .02* |
| Mediastinal involvement, no. (%) | 105 (48) | 70 (51) | 35 (42) | 26 (56) | 79 (45) | 78 (51) | 27 (40) | NS |
| CNS involvement, no. (%) | 20 (9) | 10 (7) | 10 (11) | 4 (9) | 16 (9) | 13 (8) | 7 (10) | NS |
| CR, no. (%) | 214 (92) | 136 (96) | 78 (87) | 41 (89) | 173 (93) | 150 (94) | 64 (88) | NS |
| Relapse, no. (%) | 94 (44) | 48 (35) | 46 (59) | 18 (44) | 76 (44) | 55 (37) | 39 (61) | .001* |
NS indicates not significant.
P < .05